HUP0101465A3 - Process for alkylating hindered sulfonamides effective as matrix metalloproteinase inhibitors - Google Patents
Process for alkylating hindered sulfonamides effective as matrix metalloproteinase inhibitorsInfo
- Publication number
- HUP0101465A3 HUP0101465A3 HU0101465A HUP0101465A HUP0101465A3 HU P0101465 A3 HUP0101465 A3 HU P0101465A3 HU 0101465 A HU0101465 A HU 0101465A HU P0101465 A HUP0101465 A HU P0101465A HU P0101465 A3 HUP0101465 A3 HU P0101465A3
- Authority
- HU
- Hungary
- Prior art keywords
- effective
- matrix metalloproteinase
- metalloproteinase inhibitors
- alkylating
- sulfonamides
- Prior art date
Links
- 230000002152 alkylating effect Effects 0.000 title 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8131098P | 1998-04-10 | 1998-04-10 | |
| PCT/US1999/007858 WO1999052862A1 (en) | 1998-04-10 | 1999-04-09 | Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0101465A2 HUP0101465A2 (hu) | 2002-03-28 |
| HUP0101465A3 true HUP0101465A3 (en) | 2002-11-28 |
Family
ID=22163376
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0101465A HUP0101465A3 (en) | 1998-04-10 | 1999-04-09 | Process for alkylating hindered sulfonamides effective as matrix metalloproteinase inhibitors |
| HU9901043A HUP9901043A1 (hu) | 1998-04-10 | 1999-04-09 | Gátolt szulfonamidok alkilezésére szolgáló eljárás és az eljárással előállított köztitermékek |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9901043A HUP9901043A1 (hu) | 1998-04-10 | 1999-04-09 | Gátolt szulfonamidok alkilezésére szolgáló eljárás és az eljárással előállított köztitermékek |
Country Status (47)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458822B2 (en) | 2000-03-13 | 2002-10-01 | Pfizer Inc. | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases |
| EP1134207A1 (en) * | 2000-03-15 | 2001-09-19 | Pfizer Products Inc. | Process for preparing resorcinol derivatives |
| US6548667B2 (en) | 2000-04-07 | 2003-04-15 | Samsung Electronics Co. Ltd. | Sulfonamide derivative as a matrix metalloproteinase inhibitor |
| US20020073441A1 (en) | 2000-12-13 | 2002-06-13 | Ross Brian D. | Compositions and methods for detecting proteolytic activity |
| US6844373B2 (en) * | 2002-05-28 | 2005-01-18 | Alcatel | Composition comprising fluorinated, radiation-curable dyes for surface energy control |
| JP2006516548A (ja) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 迅速ゲル化ポリマー組成物からの薬物送達法 |
| ITFI20040174A1 (it) * | 2004-08-03 | 2004-11-03 | Protera S R L | Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi |
| ITBO20050005U1 (it) * | 2005-01-31 | 2006-08-01 | Ali Spa | Distributore di bevande ghiacciate e simili |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA794723B (en) | 1978-09-11 | 1980-08-27 | Univ Miami | Anti-hypertensive agents |
| GB9000725D0 (en) | 1990-01-12 | 1990-03-14 | Pfizer Ltd | Therapeutic agents |
| US5506242A (en) | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| PL331895A1 (en) * | 1996-08-23 | 1999-08-16 | Pfizer | Arylosulphonylamino derivatives of hydroxamic acid |
| BR9807815A (pt) | 1997-02-03 | 2000-03-08 | Pfizer Prod Inc | Derivados de ácido arilsulfonilamino-hidroxâmico |
| DK0895988T3 (da) | 1997-08-08 | 2002-09-09 | Pfizer Prod Inc | Arylsulfonylaminohydroxamsyrederivater |
| EA002490B1 (ru) | 1997-08-08 | 2002-06-27 | Пфайзер Продактс Инк. | Производные арилоксиарилсульфониламиногидроксамовой кислоты |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
-
1999
- 1999-03-24 PA PA19998469601A patent/PA8469601A1/es unknown
- 1999-03-25 ES ES99302287T patent/ES2163316T3/es not_active Expired - Lifetime
- 1999-03-25 EP EP99302287A patent/EP0949245B1/en not_active Expired - Lifetime
- 1999-03-25 DE DE69900321T patent/DE69900321T2/de not_active Expired - Fee Related
- 1999-03-25 IL IL12916899A patent/IL129168A/xx not_active IP Right Cessation
- 1999-03-25 AT AT99302287T patent/ATE206392T1/de not_active IP Right Cessation
- 1999-03-25 PT PT99302287T patent/PT949245E/pt unknown
- 1999-03-25 DK DK99302287T patent/DK0949245T3/da active
- 1999-03-25 GT GT199900047A patent/GT199900047A/es unknown
- 1999-04-01 OA OA9900073A patent/OA11030A/en unknown
- 1999-04-05 ID IDP990304D patent/ID23244A/id unknown
- 1999-04-06 PE PE1999000277A patent/PE20000417A1/es not_active Application Discontinuation
- 1999-04-06 IS IS5018A patent/IS5018A/is unknown
- 1999-04-07 SK SK453-99A patent/SK45399A3/sk unknown
- 1999-04-07 MA MA25530A patent/MA24833A1/fr unknown
- 1999-04-07 IN IN522DE1999 patent/IN192485B/en unknown
- 1999-04-07 TN TNTNSN99054A patent/TNSN99054A1/fr unknown
- 1999-04-07 DZ DZ990055A patent/DZ2754A1/xx active
- 1999-04-07 KR KR1019990011957A patent/KR100357660B1/ko not_active IP Right Cessation
- 1999-04-07 TW TW088105541A patent/TW520354B/zh not_active IP Right Cessation
- 1999-04-08 TR TR1999/00756A patent/TR199900756A2/xx unknown
- 1999-04-08 YU YU18399A patent/YU18399A/sh unknown
- 1999-04-08 CA CA002268684A patent/CA2268684C/en not_active Expired - Fee Related
- 1999-04-08 AP APAP/P/1999/001506A patent/AP1095A/en active
- 1999-04-08 EG EG37499A patent/EG21985A/xx active
- 1999-04-08 SG SG1999001651A patent/SG75167A1/en unknown
- 1999-04-08 AR ARP990101601A patent/AR017731A1/es active IP Right Grant
- 1999-04-09 TR TR2000/02950T patent/TR200002950T2/xx unknown
- 1999-04-09 UA UA99042034A patent/UA57039C2/uk unknown
- 1999-04-09 HU HU0101465A patent/HUP0101465A3/hu unknown
- 1999-04-09 PL PL99332451A patent/PL332451A1/xx unknown
- 1999-04-09 HN HN1999000043A patent/HN1999000043A/es unknown
- 1999-04-09 NZ NZ335105A patent/NZ335105A/xx unknown
- 1999-04-09 CN CN99804961A patent/CN1296474A/zh active Pending
- 1999-04-09 EP EP99917394A patent/EP1068180B1/en not_active Expired - Lifetime
- 1999-04-09 CA CA002327498A patent/CA2327498C/en not_active Expired - Fee Related
- 1999-04-09 DE DE69922638T patent/DE69922638T2/de not_active Expired - Fee Related
- 1999-04-09 RU RU2000125555/04A patent/RU2197479C2/ru not_active IP Right Cessation
- 1999-04-09 PL PL99343530A patent/PL343530A1/xx unknown
- 1999-04-09 NO NO991675A patent/NO991675L/no not_active Application Discontinuation
- 1999-04-09 ID IDW20002031A patent/ID27208A/id unknown
- 1999-04-09 IL IL13877899A patent/IL138778A0/xx unknown
- 1999-04-09 HR HR990106A patent/HRP990106B1/xx not_active IP Right Cessation
- 1999-04-09 CN CN99104932A patent/CN1234396A/zh active Pending
- 1999-04-09 US US09/289,454 patent/US6114568A/en not_active Expired - Fee Related
- 1999-04-09 ZA ZA9902627A patent/ZA992627B/xx unknown
- 1999-04-09 EA EA199900277A patent/EA002277B1/ru not_active IP Right Cessation
- 1999-04-09 KR KR10-2000-7011232A patent/KR100377718B1/ko not_active IP Right Cessation
- 1999-04-09 BG BG103320A patent/BG63665B1/bg unknown
- 1999-04-09 ES ES99917394T patent/ES2234253T3/es not_active Expired - Lifetime
- 1999-04-09 AU AU35527/99A patent/AU760213B2/en not_active Ceased
- 1999-04-09 AT AT99917394T patent/ATE284864T1/de not_active IP Right Cessation
- 1999-04-09 JP JP2000543425A patent/JP3479511B2/ja not_active Expired - Fee Related
- 1999-04-09 AU AU23691/99A patent/AU755004B2/en not_active Ceased
- 1999-04-09 WO PCT/US1999/007858 patent/WO1999052862A1/en active IP Right Grant
- 1999-04-09 US US09/290,022 patent/US6229025B1/en not_active Expired - Fee Related
- 1999-04-09 HU HU9901043A patent/HUP9901043A1/hu unknown
- 1999-04-09 BR BR9910110-6A patent/BR9910110A/pt not_active IP Right Cessation
- 1999-04-09 BR BR9902219-2A patent/BR9902219A/pt not_active IP Right Cessation
- 1999-04-12 JP JP10387399A patent/JP3540959B2/ja not_active Expired - Fee Related
- 1999-04-12 CO CO99021411A patent/CO4810299A1/es unknown
- 1999-04-12 UY UY25469A patent/UY25469A1/es unknown
- 1999-05-05 SA SA99200089A patent/SA99200089A/ar unknown
-
2000
- 2000-08-25 CN CN00126476A patent/CN1288885A/zh active Pending
- 2000-10-02 ZA ZA200005370A patent/ZA200005370B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL150712A0 (en) | Matrix metalloproteinase inhibitors | |
| IL146518A0 (en) | Metalloprotease inhibitors | |
| IL146288A0 (en) | Vla-4 inhibitor compounds | |
| IL144168A0 (en) | 2,3,4,5,-tetrahydro-1h-[1,4] benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors | |
| PL350452A1 (en) | Dihetero-substituted metalloprotease inhibitors | |
| HK1045501A1 (zh) | 作為基質金屬蛋白酶抑制劑的異羥肟酸衍生物 | |
| AU6764400A (en) | Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors | |
| IL139248A0 (en) | Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors | |
| HUP0101300A3 (en) | Matrix metalloprotease inhibitors | |
| HUP0101465A3 (en) | Process for alkylating hindered sulfonamides effective as matrix metalloproteinase inhibitors | |
| IL137162A0 (en) | 2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors | |
| HUP0302904A3 (en) | Matrix metalloproteinase inhibitors | |
| GB9707333D0 (en) | Metalloproteinase inhibitors | |
| IL142301A0 (en) | Benzamide derivatives as thrombin inhibitors | |
| IL132843A0 (en) | Metalloproteinase inhibitors | |
| SI1060161T1 (en) | Matrix metalloproteinase inhibitors | |
| GB9702085D0 (en) | Matrix metalloproteinase inhibitors | |
| SI1109560T1 (en) | Compounds useful as aicarft inhibitors | |
| GB9714548D0 (en) | Matrix metalloproteinase inhibitors | |
| HUP9902606A3 (en) | Matrix metalloproteinase inhibitors | |
| GB9818830D0 (en) | Hydroxamic acid derivatives as proteinase inhibitors | |
| SI1181017T1 (en) | Metalloprotease inhibitors | |
| GB9707313D0 (en) | Metalloproteinase Inhibitors | |
| GB9708571D0 (en) | Metalloproteinase inhibitors | |
| GB9713472D0 (en) | Metalloproteinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |